04.27.26 -- The Industrialization Of Advanced Modalities

Antibody-drug conjugate (ADC) development requires tightly integrated manufacturing. Streamlined, end-to-end solutions reduce complexity, improve quality, and accelerate time-to-market.

Developing robust, scalable microbial fermentation depends on optimizing growth and expression phases through oxygen transfer, fine-tuning of nutrient delivery, and induction of protein expression.

A new regulatory chapter requires holistic, real‑world testing of injectable systems, mandating full‑system validation with actual drug products and prioritizing patient‑centric performance and safety.

Choosing licensed vs. unlicensed cell lines impacts development speed, cost, flexibility, and long‑term control, making early strategic evaluation key to efficient biologics development.

Experts note CGT programs often struggle due to limited operational readiness; early standardization supports scalable, reproducible, regulatory‑ready development and helps prevent late‑stage bottlenecks.

By integrating scalable operations, reliable supply chains, and deep regulatory expertise, biotech companies can eliminate bottlenecks, improve efficiency, and accelerate trial execution.

Sterile site unites advanced filling tech, integrated quality, and scalable capacity to streamline complex injectables, reduce risk, and support efficient progress to commercial supply.

A robust formulation development approach integrates scientific principles, systematic formulation development, and preclinical models to facilitate identification of candidates with poor developability.

Explore the advancements in ADCs that focus on high-DAR, multispecific designs, and novel payloads, while addressing challenges in manufacturability, scalability, regulatory acceptance, and viability.

Drug developers must successfully navigate the path to market, under the growing pressure of regulation and competition, and while carefully managing technical and financial risk.

This session highlights common late-stage risks and discusses how a stronger stability design can support confident IND, BLA, and long-term supply strategies.

This case study shows how smart formulation and integrated development achieved a stable 180 mg/mL biologic for subcutaneous delivery, for teams tackling concentration issues.